Navigation Links
Keystone Nano Announces Start Of Clinical Testing Of Ceramide NanoLiposome For The Improved Treatment Of Cancer
Date:4/6/2017

STATE COLLEGE, Pa., April 6, 2017 /PRNewswire/ -- Keystone Nano, Inc., a biopharmaceutical company focused on improving cancer treatments through the application of nanotechnology, announced today that clinical testing has been started for Ceramide NanoLiposome.  The therapy is being tested at three leading cancer Institutes:

  • the Greenebaum Cancer Center of the University of Maryland,
  • the Medical University of South Carolina, and
  • the University of Virginia Cancer Center.

These Centers will conduct the Phase I clinical trial to assess Ceramide NanoLiposome in the treatment of solid tumors.  Dr. Mark Kester, Keystone Nano's Chief Medical Officer and the Director of the University of Virginia's NanoSTAR program, and the original developer of Ceramide NanoLiposome remarked: "I am very pleased this has reached the clinic.  Primary liver cancer is a devastating disease with incredibly poor outcomes and very few treatment options.  Ceramide NanoLiposome offers the potential to increase treatment options for these patients."  

"This is the first step in achieving one of the primary goals of Keystone Nano, to apply nanotechnology to create new therapeutic opportunities that cannot be pursued without our novel nanoscale platforms," noted Dr. James Adair, Keystone Nano's Chief Science Officer. 

Ceramide is a biologically active lipid that has shown efficacy in multiple models of liver cancer, as well as in breast cancer, leukemia and pancreatic cancer.  Evidence collected in a large number of research tests (in vitro and in vivo) has clearly demonstrated that Ceramide NanoLiposome kills cancer cells while leaving normal cells alone, providing treatment without undue toxicity. 

The Phase I portion of the trial will recruit patients with solid tumors to establish dosing and safety.  The Phase II component of the trial is expected to focus on Liver Cancer, which kills approximately 27,000 people in the United States and 700,000 worldwide each year.  There is currently no effective therapy for this disease.  Keystone Nano was recently awarded orphan drug status for the treatment of liver cancer with ceramides in the United States.

About Keystone Nano, Inc.  Based in State College KN is working at the interface between nanotechnology and medicine. In addition to developing Ceramide NanoLiposome, the company is working on additional products using NanoJackets for RNA delivery. For more information visit www.keystonenano.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/keystone-nano-announces-start-of-clinical-testing-of-ceramide-nanoliposome-for-the-improved-treatment-of-cancer-300436081.html


'/>"/>
SOURCE Keystone Nano, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Applied BioMath, LLC presents work in immuno-oncology and antibody drug-conjugates at Keystone Symposium
2. MaxCyte, Inc. to Present Pre-Clinical Data for Targeted Gene-Correction in a Rare Disease at Keystone Symposia on Precision Genome Engineering
3. University City Keystone Innovation Zone Expands to Old City, N3rd Street Startup Community
4. Keystone Symposia Announces Grant from Alfred P. Sloan Foundation for an Advanced Life Sciences Training Program
5. Maxwell Biotech Venture Funds Portfolio Company Hepatera LLC Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta
6. The Conference Forum Announces "Rational Combinations 360°" Conference in June in NYC
7. BERG Announces BPM 31510 Data Presentations at 2017 AACR in Immuno-Oncology, Glioblastoma Mutiforme, Pancreatic Cancers and Novel Prostate Cancer Biomarker Panel
8. Cynvenio Biosystems Announces Expansion of Payer Network with Addition of Blue Cross Blue Shield of Illinois
9. United Therapeutics Announces Decision From Patent Trial And Appeal Board And Issuance Of New Patents
10. BioAmber Announces CFO Transition
11. RenovoRx Announces FDA Clearance for Expanded Labeling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2018)... ... August 01, 2018 , ... ... research results on the significant impact of a proprietary biofield energy treated ... The preclinical research assessed biomarkers for systemic and organ-specific inflammation, as well ...
(Date:7/26/2018)... (PRWEB) , ... July 26, 2018 , ... ... based on the impact of a biofield energy treated nutraceutical to improve anti-inflammatory ... as, immune function response assessed in the preclinical research, were significantly reduced. Results ...
(Date:7/25/2018)... ... July 25, 2018 , ... ... clinical trial patient and supplies data through its flagship IXRS® 3 Interactive ... Best Practices.” , This podcast features both Almac thought leaders and outside experts ...
(Date:7/24/2018)... , ... July 24, 2018 , ... ... iteration of their highly successful SmartTRAK platform. Not just a pretty face, ... simplicity and speed. , SmartTRAK is the world’s first online and real-time ...
Breaking Biology Technology:
(Date:7/31/2018)... ... 31, 2018 , ... GSL Biotech has released a new integration ... leading cloud-based Electronic Lab Notebook (ELN) platform. , SnapGene specializes in the visualization ... their research data records in a secure, compliant online platform. Among the data ...
(Date:7/30/2018)... ... 2018 , ... TC Slade, an evidence-based healer, today released ... treated Vitamin D3 on the strength and health of bones. , The ... ALP, a bone-specific enzyme ,     Over 240% increase in collagen levels , ...
(Date:7/28/2018)... ... July 28, 2018 , ... Professor You-Lin ... University (PolyU), has been honoured with the International Association for Wind Engineering (IAWE) ... engineering and bridge engineering in research, education, and application. Professor Xu is the ...
Breaking Biology News(10 mins):